MRNA VACCINE PLATFORM FOR NON-COVID DISEASES: UPDATES IN CANCER, HIV, AND INFLUENZA THERAPEUTICS

Abstract

Messenger RNA (mRNA) vaccine technology has emerged as one of the most transformative biomedical innovations of the twenty-first century, particularly following the global success of mRNA vaccines during the COVID-19 pandemic. Beyond SARS-CoV-2 prevention, mRNA vaccine platforms are increasingly being investigated for numerous non-COVID diseases including cancer, human immunodeficiency virus (HIV), influenza, and other infectious and chronic disorders. Unlike conventional vaccine technologies, mRNA vaccines provide rapid design flexibility, scalable manufacturing, enhanced immunogenicity, and precise antigen targeting while avoiding risks associated with live attenuated pathogens. Advances in lipid nanoparticle delivery systems, nucleoside modifications, computational immunology, and synthetic biology have significantly expanded the therapeutic potential of mRNA-based platforms.Cancer immunotherapy represents one of the most promising applications of mRNA vaccines due to their ability to encode tumor-associated antigens and stimulate adaptive immune responses. Personalized neoantigen-based cancer vaccines are currently under clinical evaluation for melanoma, lung cancer, colorectal cancer, and other malignancies. Similarly, HIV vaccine development has benefited from mRNA technologies capable of generating broadly neutralizing antibodies and enhancing cellular immunity. Influenza vaccine research also increasingly utilizes mRNA systems to improve strain adaptability, immunogenicity, and pandemic preparedness.Pharmacists contribute significantly to mRNA vaccine implementation through medication management, vaccine storage optimization, patient counseling, pharmacovigilance, public health education, and interdisciplinary collaboration. Despite remarkable progress, several challenges remain regarding long-term stability, manufacturing scalability, cold-chain logistics, vaccine hesitancy, regulatory pathways, and equitable global distribution.This manuscript reviews recent updates in mRNA vaccine platforms for non-COVID diseases with emphasis on cancer therapeutics, HIV prevention, influenza vaccines, pharmacist interventions, technological innovations, clinical applications, safety considerations, and future perspectives in precision immunotherapy and global healthcare.